Sign in
Companies / PFE vs REGN

PFE vs REGN: Pfizer and Regeneron Pharmaceuticals

Pharmaceuticals and Biotechnology
Compare more companies

Pfizer (PFE) reported $62.6B in revenue against a 12.4% net margin, while Regeneron Pharmaceuticals (REGN) reported $14.3B at a 31.4% net margin, most recently.

MetricPFEREGN
Revenue$62.6B$14.3B
Net Income$7.8B$4.5B
Gross Margin74.3%—
Operating Margin—24.9%
EPS (Diluted)$1.36$41.48
Free Cash Flow$9.1B$4.1B
Total Debt$64.8B$2.7B
P/E Ratio18.3×18.6×
P/B Ration/mn/m
Stock Price$29.90$910.75
Free: last 5 years
Fiscal yearFY2008 🔒FY2009 🔒FY2010 🔒FY2011 🔒FY2012 🔒FY2013 🔒FY2014 🔒FY2015 🔒FY2016 🔒FY2017 🔒FY2018 🔒FY2019 🔒FY2020 🔒FY2021FY2022FY2023FY2024FY2025
PFE Revenue•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$81.3B$101.2B$59.6B$63.6B$62.6B
REGN Revenue•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••$16.1B$12.2B$13.1B$14.2B$14.3B

More on PFE

More on REGN

Other comparisons